Magnetic resonance imaging of the bone marrow in lymphomas and leukemias.
This article reviews MRI techniques and results in the assessment of bone marrow in patients with lymphoma. MRI is more sensitive than blind biopsy (BB) in detecting bone marrow invasion. False-negative results have been reported in low-grade non Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. Bone marrow imaging is particularly indicated in patients with Hodgkin's disease, high grade NHL or myelocytic leukemia, with a negative BB and abnormal clinical (stage B, bone pains) or biochemical data (elevated alkaline phosphatase) and who have relapsed. During treatment. MR imaging is a valuable tool for the evaluation of response and the diagnosis of benign bone marrow complications. Knowledge of post-therapeutic patterns is essential to avoid misinterpretations. The main drawback with this technique is its inability to differentiate residual lesions from fibrosis and needle guided-biopsy is mandatory if treatment decision-making relies on the MR result, alone.
Tardivon
A A
AA
Department of Radiology, Institut Gustave Roussy, Villejuif, France.
Vanel
D
D
Munck
J N
JN
Bosq
J
J
D000293:Adolescent; D001853:Bone Marrow / Q000473:pathology* / Q000528:radiation effects; D006689:Hodgkin Disease / Q000175:diagnosis; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D008223:Lymphoma / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging / Q000379:methods